AMGN

SEC source: 0001127602-22-013871 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,340

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 12,296 RSUs which vest in one installment of 6,056 on 11/1/2022 and one installment of 6,240 on 11/1/2023; 2,268 RSUs which vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,193 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-22-013872 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,869

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plan: 154 RSUs which vest on 5/3/2023; 284 RSUs which vest in one installment of 140 on 5/5/2023 and one installment of 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 515 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013873 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,344

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 554 RSUs which will vest on 7/31/2022; 142 RSUs which vest in one installment of 142 on 5/3/2023; 201 RSUs which will vest in an installment of 99 on 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 140 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013875 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,006

F1 · balance_after: These shares include the following RSUs granted under the Amgen Inc. 2009 Equity Incentive Plan: 144 RSUs which vest on 5/3/2023; 269 RSUs which vest in installments of 132 on 5/5/2023 and 137 on 5/5/2024; 392 RSUs which vest in two installments of 129 on 4/30/2023 and 4/30/2024 and one installment of 134 on 4/30/2025; 350 RSUs which vest in two installments of 175 on 11/5/2022 and 11/5/2023; and 866 RSUs which will vest in installments of 285 on 5/2/2024, 286 on 5/2/2025, and 295 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 52 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013874 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,404

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 67 RSUs which vest in an installment of 67 on 5/3/2023; 114 RSUs which vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment of 495 on 11/2/2024; 300 RSUs which vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025; 350 RSUs which will vest in two installments of 175 on 11/5/2022 and 11/5/2023; and 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 99 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013876 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,307

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 4,363 RSUs which will vest on 11/2/2022; 1,534 RSUs which will vest on 5/3/2023; 2,325 RSUs which vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 897 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013877 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,661

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,342 RSUs which vest on 5/3/2023; 2,268 RSUs which vest in installments of 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,964 RSUs which vest in two installments of 1,308 on 4/30/2023 and 4/30/2024 and one installment of 1,348 on 4/30/2025; and 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 396 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013339 · form4.xml · nonDerivative · entry 2

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 621,858

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 5,369 RSUs which will vest in an installment of 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025; and 13,781 RSUs which will vest in installments of 4,547 on 5/2/2024, 4,548 on 5/2/2025, and 4,686 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,688 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013343 · form4.xml · nonDerivative · entry 2

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,387

F2 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,534 RSUs which vest in one installment of 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025; and 4,330 vest in installments of 1,428 on 5/2/2024, 1,429 on 5/2/2025, and 1,473 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 494 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013345 · form4.xml · nonDerivative · entry 2

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,407

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,074 RSUs which will vest in one installment of 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025; and 3,377 RSUs which vest in two installments of 1,114 on 5/2/2024 and 5/2/2025, and 1,149 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 902 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013348 · form4.xml · nonDerivative · entry 2

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,381

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 554 RSUs which will vest on 7/31/2022; 142 RSUs which vest in one installment of 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 145 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013350 · form4.xml · nonDerivative · entry 2

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,419

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 67 RSUs which vest in an installment of 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment of 495 on 11/2/2024; 300 RSUs which vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025; 350 RSUs which will vest in two installments of 175 on 11/5/2022 and 11/5/2023; and 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 102 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013351 · form4.xml · nonDerivative · entry 2

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,055

F2 · balance_after: These shares include the following RSUs granted under the Amgen Inc. 2009 Equity Incentive Plan: 144 RSUs which vest on 5/3/2023; 401 RSUs which vest in two installments of 132 on 5/5/2022 and 5/5/2023 and one installment of 137 on 5/5/2024; 392 RSUs which vest in two installments of 129 on 4/30/2023 and on 4/30/2024 and 134 on 4/30/2025; 350 RSUs which vest in two installments of 175 on 11/5/2022 and 11/5/2023; and 866 RSUs which will vest in installments of 285 on 5/2/2024, 286 on 5/2/2025, and 295 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 59 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013352 · form4.xml · nonDerivative · entry 2

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,882

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 4,363 RSUs which will vest on 11/2/2022; 1,534 RSUs which will vest on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 967 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013353 · form4.xml · nonDerivative · entry 2

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,250

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,342 RSUs which vest on 5/3/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,964 RSUs which vest in two installments of 1,308 on 4/30/2023 and 4/30/2024 and one installment of 1,348 on 4/30/2025; and 3,637 RSUs which will vest in two installments of 1,200 on 5/2/2024 and on 5/2/2025, and one installment of 1,237 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 465 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013336 · form4.xml · nonDerivative · entry 1

Kullman Ellen Jamison · CIK 0001303141 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,752.8165

F1 · balance_after: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended (the Director Program), under the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and vest immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the deferral schedule.

F2 · balance_after: These shares include 678 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013338 · form4.xml · nonDerivative · entry 1

ISHRAK OMAR · CIK 0001523102 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,075.7414

F1 · balance_after: The Restricted Stock Units (RSUs) were granted, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.

SEC source: 0001127602-22-013339 · form4.xml · derivative · entry 3

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,508

Underlying: Common Stock · 112,508 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively

SEC source: 0001127602-22-013339 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 624,550

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013343 · form4.xml · derivative · entry 3

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,704

Underlying: Common Stock · 35,352 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013343 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,195

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013345 · form4.xml · derivative · entry 3

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,574

Underlying: Common Stock · 27,574 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013345 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,973

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013346 · form4.xml · derivative · entry 2

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,817

Underlying: Common Stock · 31,817 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013346 · form4.xml · nonDerivative · entry 1

Griffith Peter H. · CIK 0001798821 · EVP & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,929

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 12,296 RSUs which vest in one installment of 6,056 on 11/1/2022 and one installment of 6,240 on 11/1/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; 3,338 RSUs which vest in installments of 1,101 on 4/30/2023, 1,102 on 4/30/2024 and 1,135 on 4/30/2025; and 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and 1,325 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 1,262 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.

SEC source: 0001127602-22-013347 · form4.xml · derivative · entry 4

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,302

Underlying: Common Stock · 5,302 shares

Expires 2032-05-02

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013347 · form4.xml · nonDerivative · entry 2

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,921

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plan: 154 RSUs which vest in one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023; and 649 RSUs which will vest in two installments of 214 on 5/2/2024 and 5/2/2025, and one installment of 221 on 5/2/2026. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 523 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-013347 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,978

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013348 · form4.xml · derivative · entry 3

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,949

Underlying: Common Stock · 4,949 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013348 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,434

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013350 · form4.xml · derivative · entry 3

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,535

Underlying: Common Stock · 3,535 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013350 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,437

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013351 · form4.xml · derivative · entry 3

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,070

Underlying: Common Stock · 7,070 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013351 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,109

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013352 · form4.xml · derivative · entry 3

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,817

Underlying: Common Stock · 31,817 shares

Expires 2032-05-02

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013352 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,652

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013353 · form4.xml · derivative · entry 4

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,695

Underlying: Common Stock · 29,695 shares

Expires 2032-05-02

F5 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-013353 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,958

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2024, 5/2/2025 and 5/2/2026, respectively.

SEC source: 0001127602-22-012758 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,769

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 10,580 RSUs which vest in installments of 5,211 on 5/3/2022 and 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; and 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,174 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012759 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,596

F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 999 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012761 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,329

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 452 RSUs which will vest in one installment on 5/3/2022 and one installment of 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 536 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012763 · form4.xml · nonDerivative · entry 1

Khosla Rachna · CIK 0001881332 · SVP, Business Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,828

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 554 RSUs which will vest on 7/31/2022; 280 RSUs which vest in installments of 138 on 5/3/2022 and 142 on 5/3/2023; 300 RSUs which will vest in two installments of 99 on 5/5/2022 and 5/5/2023 and one installment of 102 on 5/5/2024; 375 RSUs which will vest in installments of 123 on 4/30/2023, 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012764 · form4.xml · nonDerivative · entry 1

Louie Linda H. · CIK 0001818953 · VP, Finance & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,004

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 132 RSUs which vest in installments of 65 on 5/3/2022 and 67 on 5/3/2023; 169 RSUs which vest in installments of 55 on 5/5/2022, 56 on 5/5/2023 and 58 on 5/5/2024; 1,453 RSUs which vest in two installments of 479 on 11/2/2022 and 11/2/2023 and one installment of 495 on 11/2/2024; 300 RSUs which vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025; and 350 RSUs which will vest in two installments of 175 on 11/5/2022 and 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 107 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012765 · form4.xml · nonDerivative · entry 1

Miller Derek · CIK 0001917312 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,243

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 283 RSUs which vest in installments of 139 on 5/3/2022 and 144 on 5/3/2023; 401 RSUs which vest in two installments of 132 on 5/5/2022 and 5/5/2023 and one installment of 137 on 5/5/2024; 392 RSUs which vest in two installments of 129 on 4/30/2023 and on 4/30/2024 and 134 on 4/30/2025; and 350 RSUs which vest in two installments of 175 on 11/5/2022 and 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 71 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012766 · form4.xml · nonDerivative · entry 1

REESE DAVID M · CIK 0001748434 · EVP, Research and Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,755

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 4,363 RSUs which will vest on 11/2/2022; 3,023 RSUs which will vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,006 RSUs which vest in installments of 1,321 on 4/30/2023, 1,322 on 4/30/2024 and 1,363 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,105 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-012767 · form4.xml · nonDerivative · entry 1

Santos Esteban · CIK 0001677950 · EVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,321

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,645 RSUs which vest in installments of 1,303 on 5/3/2022 and 1,342 on 5/3/2023; 3,384 RSUs which vest in installments of 1,116 on 5/5/2022, 1,117 on 5/5/2023 and 1,151 on 5/5/2024; and 3,964 RSUs which vest in two installments of 1,308 on 4/30/2023 and 4/30/2024 and 1,348 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 586 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-010185 · form4.xml · nonDerivative · entry 1

Bradway Robert A · CIK 0001396482 · Director · Chairman, CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 613,316

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 4,790 RSUs which will vest on 4/27/2022; 10,580 RSUs which vest in installments of 5,211 on 5/3/2022 and 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; and 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 2,773 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-010186 · form4.xml · nonDerivative · entry 1

Gordon Murdo · CIK 0001642156 · EVP Global Commercial Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,865

F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 3,023 RSUs which vest in installments of 1,489 on 5/3/2022 and 1,534 on 5/3/2023; 3,469 RSUs which vest in installments of 1,144 on 5/5/2022, 1,145 on 5/5/2023 and 1,180 on 5/5/2024; and 4,172 RSUs which vest in installments of 1,376 on 4/30/2023, 1,377 on 4/30/2024 and 1,419 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 632 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-010188 · form4.xml · nonDerivative · entry 1

Graham Jonathan P · CIK 0001365306 · EVP, Gen. Counsel & Secy.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,195

F1 · balance_after: These shares include the following Restricted Stock Units granted under the Company's equity plans: 1,073 RSUs which will vest on 4/27/2022; 2,116 RSUs which vest in installments of 1,042 on 5/3/2022 and 1,074 on 5/3/2023; 6,148 RSUs which vest in one installment of 3,028 on 11/1/2022 and one installment of 3,120 on 11/1/2023; 3,300 RSUs which vest in two installments of 1,089 on 5/5/2022 and 5/5/2023 and one installment of 1,122 on 5/5/2024; and 3,797 RSUs which vest in two installments of 1,253 on 4/30/2023 and 4/30/2024 and one installment of 1,291 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 1,133 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-22-010191 · form4.xml · nonDerivative · entry 1

Grygiel Nancy A. · CIK 0001816414 · SVP & CCO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,389

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 153 RSUs which will vest on 4/27/2022; 303 RSUs which vest in installments of 149 on 5/3/2022 and 154 on 5/3/2023; 423 RSUs which vest in installments of 139 on 5/5/2022, 140 on 5/5/2023 and 144 on 5/5/2024; 8,174 RSUs which will vest in two installments of 2,697 on 7/31/2022 and 7/31/2023 and one installment of 2,780 on 7/31/2024; 584 RSUs which vest in installments of 192 on 4/30/2023, 193 on 4/30/2024 and 199 on 4/30/2025; and 935 RSUs which will vest in installments of 467 on 11/5/2022 and 468 on 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 555 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.